SCOPE:
Superior Health Plan Pharmacy Department, Medical Directors

PURPOSE:
It is the policy of Superior Health Plan to follow state guidance for medical necessity review of Tisagenlecleucel (Kymria). This medication should follow state guidance for medical necessity review for Medicaid/CHIP. All determinations will be performed by a Superior Medical Director. A pharmacy clinician will review the prior authorization request and make a recommendation to the Medical Director but will not make the ultimate determination on any case.

Tisagenlecleucel (Kymria) infusions must take place at a certified healthcare facility. Certified healthcare facilities must enroll with the Risk Evaluation and Mitigation Strategies (REMS) and comply with its requirements for each drug administered within this section. Certified healthcare facilities must ensure that providers that prescribe, dispense, or administer tisagenlecleucel (Kymria) receive training for the management of cytokine release syndrome (CRS) and neurological toxicities.

Medical Directors should attempt to direct to a participating (PAR) provider. On a case by case basis, said Medical Director may make an exception outside of a PAR provider but will require a single case agreement (SCA).

In addition, the procedure code Q2040 (used for Kymria) will be limited to once per lifetime, by any provider. If the code is updated in the future it will still be limited to once per lifetime.

BACKGROUND:
Description:
Tisagenlecleucel (Kymria) is a CD19-directed genetically modified autologous T cell immunotherapy (containing human cells modified with a lentivirus) in which a patient’s T cells are reprogrammed with a transgene encoding a chimeric antigen receptor (CAR) to identify and eliminate CD19-expressing malignant and normal cells.
FDA Approved Indication(s)
Tisagenlecleucel (Kymriah) is indicated for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. Additionally, Kymriah is indicated to treat adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy (including diagnoses of diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma and DLBCL arising from follicular lymphoma).

Formulations:
Available as a single-dose unit infusion bag: frozen suspension of genetically modified autologous T cells labeled for the specific recipient.

PROCEDURE:
Provider must submit documentation (which may include office chart notes and lab results) supporting that member has met all approval criteria.

I. Initial Approval Criteria:
A. B-cell Precursor Acute Lymphoblastic Leukemia (relapsed or refractory)
1. All prior authorization approvals or denials will be determined by a Superior HealthPlan Medical Director.
2. The member is age 25 years or younger.
3. Medication is prescribed by an oncologist or in consultation with an oncologist.
4. The member has a diagnosis of B-cell acute lymphoblastic leukemia with confirmed CD-19 tumor expression.
5. The member does not have an active infection or inflammatory disorder.
6. The member does not have primary central nervous system lymphoma.
7. The Eastern Cooperative Oncology Group performance status is 0 to 3.
8. The member has not received prior CAR-T therapy.
9. The health-care facility has enrolled in the Kymriah® Risk Evaluation and Mitigation Strategies and training has been given to the provider on
the management of cytokine release syndrome and neurological toxicities.

10. If the facility is non-PAR the medical director will redirect to a PAR provider. On a case by case basis, said Medical Director may make an exception outside of a PAR provider but will require a single case agreement (SCA). Once the case is determined, the pharmacy team via pharmacy management will work with the SCA team to assist on the SCA. This should be the exception and not the rule as a PAR facility/provider is preferable. The pharmacist supporting the medical director will contact pharmacy management to start the SCA process.

Approval duration: Only 1 dose per lifetime will be provided on this drug regardless of Provider.

B. Diffuse Large B-cell Lymphoma (relapsed or refractory)

1. All prior authorization approvals or denials will be determined by a Superior HealthPlan Medical Director.
2. The member is 18 years or older.
3. Medication is prescribed by an oncologist or in consultation with an oncologist.
4. The member has a diagnosis of relapsed or refractory large B-cell lymphoma (such as diffuse large B-cell lymphoma, high grade B-cell lymphoma, diffuse large B-cell lymphoma arising from follicular lymphoma).
5. The member must have relapsed or refractory disease as progression after two or more lines of systemic therapy (which may or may not include therapy supported by autologous stem cell transplant). The member must have received adequate prior therapy including, at a minimum, the following:
   a. An anthracycline-containing chemotherapy regimen
   b. For CD20+ disease, an anti-CD20 monoclonal antibody
   c. For members with transformed follicular lymphoma, prior chemotherapy refractory disease after transformation to DLBCL
6. The member has an Eastern Cooperative Oncology Group performance status of 0 or 1.
7. The member does not have primary central nervous system lymphoma.
8. The member does not have an active infection or inflammatory disorder.
9. The member has not received prior CAR-T therapy.
10. The health-care facility has enrolled in the Kymriah® Risk Evaluation and Mitigation Strategies and training has been given to the provider on the management of cytokine release syndrome and neurological toxicities.
11. If the facility is non-PAR the medical director will redirect to a PAR provider. On a case by case basis, said Medical Director may make an exception outside of a PAR provider but will require a single case agreement (SCA). Once the case is determined, the pharmacy team via pharmacy management will work with the SCA team to assist on the SCA. This should be the exception and not the rule as a PAR facility/provider is preferable. The pharmacist supporting the medical director will contact pharmacy management to start the SCA process.

Approval duration: Only 1 dose per lifetime will be provided on this drug regardless of Provider.

REFERENCES:
Kymriah (tisagenlecleucel) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; May 2018.

For information regarding the Eastern Cooperative Oncology Group performance status please see: http://ecog-acrin.org/resources/ecog-performance-status.

ATTACHMENTS:

DEFINITIONS/Abbreviations:
**Policy and Procedure**

<table>
<thead>
<tr>
<th>DEPARTMENT: Pharmacy, Medical Directors</th>
<th>DOCUMENT NAME: Tisagenlecleucel (Kymriah)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PAGE: 5 of 5</td>
<td>REPLACES DOCUMENT:</td>
</tr>
<tr>
<td>EFFECTIVE DATE: 4/8/2019</td>
<td></td>
</tr>
</tbody>
</table>

**REVISION LOG**

<table>
<thead>
<tr>
<th>REVISION</th>
<th>DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Added REMS statement</td>
<td>9/19/2019</td>
</tr>
<tr>
<td>Changed approval duration to one dose per lifetime</td>
<td></td>
</tr>
<tr>
<td>Added exclusion criteria of primary CNS lymphoma</td>
<td></td>
</tr>
<tr>
<td>Added PAR facility statement</td>
<td></td>
</tr>
</tbody>
</table>

**POLICY AND PROCEDURE APPROVAL**

Karen Tadlock, V.P., Pharmacy Operations  
Approval on file

Dr. David Harmon, Sr. V.P., Chief Medical Officer  
Approval on file

Pharmacy & Therapeutics Committee:  
Approval on file

*NOTE: The electronic approval retained in RSA Archer, Centene's P&P management software, is considered equivalent to a physical signature.*